Wells Fargo analyst Derek Archila maintained a Hold rating on Zymeworks (ZYME – Research Report) yesterday and set a price target of $14.00.
Derek Archila has given his Hold rating due to a combination of factors related to Zymeworks’ current position and future prospects. The company is making progress with its early-stage pipeline, particularly with ZW191 and ZW171, but there are limited immediate catalysts expected to drive the stock price higher in the near term. Additionally, while the launch of zani in BTC is underway, and there are significant potential milestone payments and royalties, much of this value appears to already be reflected in the current stock price.
Furthermore, the delay in the GEA Phase 3 data to the second half of 2025, along with the company’s decision to prioritize ZW251 over ZW220, suggests a cautious approach to resource allocation. With a solid cash position extending into the second half of 2027, Zymeworks has a runway to advance its programs, but the lack of immediate, significant clinical milestones means the stock is likely to remain range-bound. As such, Archila remains on the sidelines, awaiting more substantial clinical developments and clearer financial pathways before considering a more favorable rating.
ZYME’s price has also changed moderately for the past six months – from $11.760 to $13.180, which is a 12.07% increase.